LinkedIn Corp. (NYSE: LNKD) has managed to beat earnings expectations at every single quarterly earnings report. Now the social network for professionals has reported sales growth of 56% to $393 million. Earnings came in at a loss of -$3.4 million after items, but the comparable non-GAAP earnings measured by Wall Street came in at $46.8 million versus $25.1 million a year ago. This translates to $0.39 in earnings per share (EPS). Thomson Reuters had estimates of $0.32 EPS and $385.4 million in revenue.
LinkedIn also gave guidance of between $415 million and $420 million in revenue for the coming quarter with adjusted EBITDA between $98 million and $100 million. Thomson Reuters was calling for $0.40 EPS and $438.1 million in revenue. The question to ask is whether or not LinkedIn is under-promising to over-deliver or if this is a true disappointment on the revenue guidance.
U.S. sales totaled $245.3 million and represented 62% of total revenue. Field sales channels totaled $227.6 million and represented 58% of all sales. Revenue from the online, direct sales channel totaled $165.4 million, and represented 42% of total revenue.
Top 5 Defensive Companies To Own For 2015: Oaktree Capital Group LLC (OAK)
Oaktree Capital Group, LLC (Oaktree) is a global investment management firm focused on alternative markets. Oaktree manages funds in investment strategies that fall into the six asset classes, which include distressed debt, corporate debt, control investing, convertible securities, real estate and listed equities. As of June 30, 2011, the Company�� assets under management (AUM) totaled $79.5 billion. The Company�� manager is Oaktree Capital Group Holdings GP, LLC. The Company manages assets on behalf of other institutional investors in the world, including 70 of the 100 United States pension plans, 37 states in the United States, over 350 corporations, over 300 university and charitable endowments and foundations, and over 150 non-United States institutional investors, including six of the top 10 sovereign wealth fund nations.
Funds managed by Oaktree include both separate accounts and commingled funds. The commingled funds include open-end and closed-end limited partnerships for which the Company or a subsidiary serves as the general partner or, in certain limited cases, co-general partner. Oaktree makes principal investments in these funds.
Advisors' Opinion:- [By Amanda Alix]
The investment-to-REIT model is alive and well
Before the very end of last year, those involved in the single-family purchase and rental business were largely private equity groups�like the Blackstone Group (NYSE: BX ) , Colony Financial (NYSE: CLNY ) , and Oaktree Capital (NYSE: OAK ) , which bought up distressed properties by the truckload.
Top 10 Promising Stocks To Own Right Now: ZIOPHARM Oncology Inc(ZIOP)
ZIOPHARM Oncology, Inc., a biopharmaceutical company, engages in the development and commercialization of small molecule and synthetic biology approaches to cancer therapies in the United States. The company's clinical programs include Palifosfamide, a DNA cross-linker, which is in a phase III clinical trial for the treatment of metastatic soft tissue sarcoma in the front-line setting. ZIOPHARM is also developing Palifosfamide in combination with etoposide and carboplatin in phase I clinical trial to determine safety for initiating a pivotal, adaptive phase III trial in front-line. In addition, the company, in partnership with Intrexon Corporation, is developing DNA-based therapeutics (synthetic biology) that include two phase 1 clinical-stage product candidates, both of which are DNA IL-12 to be turned on/off by an oral activator ligand. Further, it is developing Indibulin, an oral tubulin binding agent, which is in Phase 1/2 for metastatic breast cancer; and Darinaparsin , a mitochondrial- and hedgehog-targeted agent that is in a solid tumor phase I study with oral administration and has been developed intravenously for the treatment of relapsed peripheral T-cell lymphoma. The company was founded in 2003 and is headquartered in New York City, New York.
Advisors' Opinion:- [By James E. Brumley]
Four months ago, you could barely give your shares of ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) away. The company announced s on Tuesday, March 26th, that its sarcoma drug Palifosfamide had failed to meet its Phase 3 goals. Shares of ZIOP plunged from $5.13 to $1.82 in a mere day, and were trading as low as $1.51 a week and a half later.
- [By James E. Brumley]
Cancer drug investors who have been disappointed in recent results from shares of Clovis Oncology Inc. (NASDAQ:CLVS) or Nuvilex Inc. (OTCMKTS:NVLX) lately may want to take a look at ZIOPHARM Oncology Inc. (NASDAQ:ZIOP) as a replacement for either of those first two stocks. CLVS is down about 16% for the week on a less-than-flattering write-up in a Bloomberg publication, and NVLX has moved under a pair of key moving averages this week because, well, for no specific reason, but broadly because the recent wave of compelling news is already losing its potency, with most of that upside already being priced into shares (and then some) before it became official.
Top 10 Promising Stocks To Own Right Now: Pinecrest Energy Inc (PNCGF.PK)
Pinecrest Energy Inc. (Pinecrest), formerly Antler Creek Energy Corp., is a Canada-based junior oil and gas exploration company. Pinecrest is engaged in the acquisition, exploitation and development of petroleum and natural gas-related assets primarily in Western Sedimentary Basin. During the fiscal year ended July 31, 2010 (fiscal 2010), Pinecrest was engaged in two (0.4 net) wells that were drilled in the southeast Saskatchewan Bakken. On July 14, 2010, the Company acquired the Loon Properties. On July 14, 2010, Pinecrest acquired the Red Earth #1 Properties. On July 15, 2010, the Company acquired the Red Earth #2 Properties. Advisors' Opinion:- [By MLP Trader]
Here are the current top five companies in the list:
CompanySymbolEV/BOEPD/NetbackPrice/NAVEV/DACFPinecrest(PNCGF.PK)53564%4.0XLightstream(LSTMF.PK)131753%4.5XNovus(NOVUF.PK)133290%4.1XZargon(ZARFF.PK)138664%5.6XTwin Butte(TBTEF.PK)155885%5.5XOf the larger companies, one that remains obstinately near the top of the list is Lightstream . Lightstream trades at 40% of its book value and a whopping 13.4% yield.
Top 10 Promising Stocks To Own Right Now: Cadence Pharmaceuticals Inc.(CADX)
Cadence Pharmaceuticals, Inc., a biopharmaceutical company, focuses on acquiring, in-licensing, developing, and commercializing proprietary product candidates principally for use in the hospital setting in the United States and Canada. It holds rights to OFIRMEV injection, a proprietary intravenous formulation of acetaminophen for the management of pain and reduction of fever in adults and children. The company in-licenses rights to OFIRMEV from Bristol-Myers Squibb Company, which sells intravenous acetaminophen in Europe and other markets for the treatment of acute pain and fever under the Perfalgan brand name. Cadence Pharmaceuticals, Inc. was founded in 2004 and is headquartered in San Diego, California.
Advisors' Opinion:- [By Jake L'Ecuyer]
Equities Trading UP
Cadence Pharmaceuticals (NASDAQ: CADX) shot up 26.42 percent to $14.02 after Mallinckrodt plc (NYSE: MNK) announced its plans to acquire Cadence Pharma for $14.00 per share in cash.
Top 10 Promising Stocks To Own Right Now: Lanxess AG (LXS)
Lanxess AG is a Germany-based chemical holding company. Its activities are divided into three main segments. The Performance Polymers segment encompasses the activities of the Lanxess Group in the production of rubber and plastics, and includes Butyl Rubbers, Performance Butadiene Rubbers, Technical Rubber Products and Semi-Crystalline Products business units. The Advanced Intermediates segment is engaged in the development, production and marketing of industrial and fine chemicals and includes Basic Chemicals and Saltigo business units. The Performance Chemicals segment combines the Group's application-oriented activities in the field of process and functional chemicals, and includes Material Protection Products, Inorganic Pigments, Functional Chemicals, Leather, Rhein Chemie, Rubber Chemicals and Ion Exchange Resins business units. The Company operates worldwide through its subsidiaries. Advisors' Opinion:- [By Sofia Horta e Costa]
ThyssenKrupp AG (TKA), Germany�� largest steelmaker, rose to a five-week high. YOC AG (YOC) surged the most in more than three months after the mobile-phone advertising company said it sold 1.3 million euros ($1.7 million) of shares to increase capital. Lanxess AG (LXS), the chemical maker that joined the DAX in September, retreated 3.4 percent.
- [By Jonathan Morgan]
Lanxess AG (LXS), which makes specialty chemicals, plastics, and rubber used in car tires, jumped 6.6 percent to 57.21 euros. Michelin & Cie, Europe�� largest tiremaker, today reiterated its 2013 profit forecast as growing demand for high-margin tires for mining vehicles helps offset declining demand in Europe.
Top 10 Promising Stocks To Own Right Now: UPM-Kymmene Corporation (UPM1V)
UPM-Kymmene Corporation is a Finland-based paper and forest products company. The Company operates, along with its subsidiaries, in three segments: the Energy and Pulp segment is divided into three units: Energy, which includes the Company�� hydropower plant and shares in energy companies; Pulp, which includes the Company�� pulp mills, and Foster and Timber, which includes forests, wood procurement, sawmills and further processing; the Paper segment includes the Company�� paper mills, producing magazine paper, newsprint, fine papers, and specialty papers, and the Engineered materials segment is structured into two units: Label, which includes label-stock factories and slitting, and distribution terminals, and Plywood, which includes plywood mills. The Company�� other operations include the wood plastic composite unit, development units and logistic services. On October 2, 2013, it completed the sale of the wood processing mill in Aigrefeuille d'Aunis, to Groupe FP Bois. Advisors' Opinion:- [By Tom Stoukas]
UPM-Kymmene (UPM1V), a rival maker of paper, dropped 1.9 percent to 10.23 euros.
Aryzta surged 4 percent to 60.45 Swiss francs, the biggest gain since March 28. The owner of bakery brands including Delice de France and Otis Spunkmeyer posted full-year revenue of 4.5 billion euros ($6.1 billion), beating analysts��estimates of 4.43 billion euros. The company also forecast a double-digit percentage gain in 2014 earnings.
Top 10 Promising Stocks To Own Right Now: Revolution Lighting Technologies Inc (RVLT)
Revolution Lighting Technologies Inc., incorporated on December 16, 1993, designs, manufacture, market and sells commercial grade, light emitting diode (LED) replacement light bulbs and LED-based signage, channel letter and contour lighting products. The Company sells these products under the Seesmart, Array Lighting and Lumificient brand names. The Company operates in two segments: LED replacement lamps and fixtures and LED signage and lighting strips. On December 20, 2012, the Company acquired Seesmart Technologies, Inc., headquartered in Simi Valley, California. In August 2013, the Company announced that it has completed the acquisition of Relume Technologies (Relume). In October 2013, the Company announced that it has acquired a portfolio of general illumination LED lighting products, including several product lines from CMG Energy Solutions (CMG). In November 2013, the Company acquired Tri-State LED.
The Company�� LED replacement lamps and fixtures segment include the Seesmart business and the Array business, which has been integrated with the Seesmart business. The LED signage and lighting strips segment is comprised of the Lumificient business.
Advisors' Opinion:- [By Paul Ausick]
Without making too much fuss over a small-cap stock, Revolution Lighting Technologies Inc. (NASDAQ: RVLT) is seeing its share price rise by nearly 25% today after reporting results this Friday morning. Yahoo! Finance does not have any estimates for the company, but Revolution posted an operating loss of $3.1 million in the quarter, more than four times worse than its loss in the same period in 2012. Even with adjustments Revolution�� operating loss totaled $1.8 million.
No comments:
Post a Comment